Protez Pharmaceuticals' Series B Round

Protez Pharmaceuticals raised a round of funding on April 06, 2006.

Protez Pharmaceuticals entered a 20-site Phase II human clinical trial in 2008 with its lead compound, PZ-601, a antibiotic candidate focused on drug resistance in difficult to treat infections.…

Articles about Protez Pharmaceuticals' Series B Round: